The Davos Alzheimer’s Collaborative (DAC) is the first global alliance of governments, nonprofits, academics and the private sector driving an unprecedented worldwide effort to combat Alzheimer’s Disease. DAC is investing over $700 million over six years to link, scale and build on existing efforts across every sector, and foster an innovation ecosystem to change the trajectory of the disease.

Why We Must Act Now:
- **The cost and reach of Alzheimer’s is staggering despite ongoing efforts to combat the disease:** Alzheimer’s and dementia impacted more than 55 million families worldwide and cost the global economy $1.3 trillion in 2019 – and are projected to reach an estimated cost of $20 trillion over the next decade.
- **Lack of diversity has limited our ability to understand the disease and develop treatments:** To date, nearly all genetic analysis has been conducted on white populations of Western European origin, leaving out 90% of the world, which has impacted progress in treatment and finding a cure. Yet more than 70% of Alzheimer’s cases will be in low- and middle-income countries by 2050 due to rapid global life expectancy.
- **Healthcare systems are not prepared to meet the challenge:** The number of people living with Alzheimer’s is projected to triple from 50 million today to over 139 million by 2050. To respond effectively, each nation’s healthcare system must create a patient pathway for brain health that will lead to greater detection, diagnosis, treatment and care for the millions who need it.

DAC, launched in 2021 by the World Economic Forum and the Global CEO Initiative on Alzheimer’s Disease, is the largest global effort of its kind – linking research, clinical trials and health systems to help people worldwide, including those in low- and middle-income countries left out of previous efforts to fight Alzheimer’s.

**DAC Is Driving Three Key Initiatives:**

**GLOBAL COHORTS:** DAC is building an unprecedented global partnership of one million people to diversify data and enable more targeted treatment. To date we have linked cohorts from 26 countries across North America, South America, Africa, Asia, Europe and the Middle East.

**CLINICAL TRIALS:** DAC is reducing the time and cost of clinical trials while improving their quality by linking a network of 90 trial sites in North America with approximately 30 European trial sites to accelerate key studies and implement novel trial designs. DAC is also piloting clinical trials in LMICs to enable access to research and innovative treatments around the globe.

**PREPARING HEALTHCARE SYSTEMS WORLDWIDE:** DAC has launched a Healthcare System Preparedness Project to fund innovative approaches that measurably increase rates of cognitive screening, early detection and accurate diagnosis. These initiatives are incorporated into DAC Learning Labs, a network of governments and healthcare system leaders, to share best practices that can be scaled globally.

[https://www.davosalzheimerscollaborative.org](https://www.davosalzheimerscollaborative.org)
What:
The Davos Alzheimer’s Collaborative (DAC) is a global effort to accelerate treatment breakthroughs, develop and scale promising research and equip healthcare systems to provide access to future advances in treatment, diagnosis and care. Among the organization’s goals are to build a global cohort of one million people that reflects the diversity of the disease to enable the discovery of new diagnostic biomarkers and interventions that will drive precision medicine and prevention for people worldwide.

The Challenge:
⇒ Progress against Alzheimer’s requires a comprehensive, nuanced understanding of the disease, yet nearly all research has been conducted on white populations of Western European origin, leaving out approximately 90% of the world. This lack of diversity limits our ability to understand the complexities of the disease, and identify new targets for treatments and associated biomarkers.

Our Progress:
DAC is building a global cohort with aspiration of reaching one million people which, to date, includes cohorts from 16 countries across North America, South America, Africa, Asia, and Europe, including low- and middle-income countries:
• Characterization: We have completed a cross-region, trans-ethnic Polygenic Risk Score (PRS) pilot that includes cohorts across the Middle East, Southeast Asia, Africa and South America.
• Integration: We have developed a roadmap for further integration of racially distinct and diverse cohorts.
• Engagement: We have secured participation from 22 cohorts representing over 130,000 diverse (non-white) people from around the globe.
• Outreach: We’ve targeted outreach to cohorts that have the strongest alignment with the scientific plan.
• We have initiated digital phenotyping by using personal digital devices to enable longitudinal data collection in populations at risk for Alzheimer’s disease.
THE DAVOS ALZHEIMER’S COLLABORATIVE

GLOBAL CLINICAL TRIALS

What:
The Davos Alzheimer’s Collaborative (DAC) is a global effort to accelerate breakthroughs, develop and scale promising solutions and equip healthcare systems to provide access to future innovations in treatment, diagnosis and care. DAC’s Global Clinical Trials initiative is building and activating a global clinical trial network and providing clinical trial support to increase the speed, efficiency and quality of Alzheimer’s clinical trials worldwide.

The Challenge:
⇒ Today, trials for Alzheimer’s treatments are slow, laborious and expensive. They require years of effort from researchers, trial participants and care partners, as well as immense biopharmaceutical investments, and still faces one of the highest failure rates in clinical development.
⇒ Coordination between trial sites is limited, inhibiting quality data collection and efficiency. Research is largely confined to North America, Europe and Japan, leaving out huge segments of the global population.
⇒ Innovation in drug development can be dramatically accelerated with faster, less costly clinical trials.

What We’re Doing:
• DAC is creating a global network of trial sites and a trial-ready technology platform to support it.
• To date, DAC has linked 90 trial sites in North America with approximately 30 European trial sites to accelerate key studies and implement novel trial designs. DAC has also identified opportunities for trials in Africa, South Korea, Singapore, Australia, Japan and China.
• DAC is also working with the other DAC initiatives to catalyze recruitment for clinical trials and development of reliable digital and blood biomarkers.
• This will allow researchers to accelerate patient recruitment and enrollment, enhance trial quality and use advanced analytics to generate scientific insights from a robust database.

2022 Milestones:
• DAC will prepare 30 trial sites in the European Network in 2022.

Where We’re Activating:

https://www.davosalzheimerscollaborative.org
THE DAVOS ALZHEIMER’S COLLABORATIVE

HEALTHCARE SYSTEM PREPAREDNESS PROGRAM

What:
The Davos Alzheimer’s Collaborative (DAC) is a global effort to accelerate breakthroughs, develop and scale promising solutions and equip healthcare systems to provide access to future innovations in treatment, diagnosis and care. DAC’s Healthcare System Preparedness Project is funding innovative approaches that measurably increase rates of cognitive screening, early detection and accurate diagnosis of Alzheimer’s. These initiatives are incorporated into DAC Learning Labs, a network of governments and healthcare system leaders, to share best practices that can be scaled globally.

The Challenge:
➢ Alzheimer’s and dementia impacted more than 55 million families worldwide and cost the global economy $1.3 trillion in 2019 – and are projected to reach an estimated cost of $20 trillion over the next decade. The aging global population, which increases the number of families with Alzheimer’s, has a dramatic impact on national budgets, global economic growth and monetary policy.
➢ Healthcare systems aren’t prepared to detect cognitive change, diagnose accurately, identify the right intervention or deliver future treatment.

What We’re Doing:
• In 2021, we designed 7 pilots in 6 countries (Japan, Jamaica, UK, Mexico, Brazil and the U.S.) focused on earlier disease detection in the primary care setting by implementing digital cognitive assessments and blood-based biomarkers in routine clinical practice.
• We issued an RFP for $2M focused on detection with the goal of crowdsourcing innovative pilots.
• We held monthly meetings with flagship sites to share learnings and problem solve, ultimately to develop a durable tool kit that can be used by healthcare systems worldwide to implement changes in their systems
• We initiated a bi-annual meeting of governments and healthcare system executives with metrics established to drive accountability.

2022 Milestones:
• Beginning with Brazil in March 2022, the early detection flagship projects will launch, focused on improving Alzheimer’s diagnosis.
• We will hold Learning Labs alongside major global health forums including Lausanne IX and the World Health Assembly.
• DAC will kick off detection grant recipient projects.
Where We’re Activating:

https://www.davosalzheimerscollaborative.org